Levosimendan Fresenius Kabi

Levosimendan, the active ingredient in Levosimendan Fresenius Kabi, is a calcium sensitizer presented as an intravenous solution for intravenous use. It enhances cardiac contractility and induces vasodilation, making it indicated for acute decompensated heart failure and cardiogenic shock in hospitalized patients.

GNH USA supplies Levosimendan Fresenius Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and specialty clinics worldwide. The company adheres to EU quality standards and provides regulatory documentation for global distribution.

Levosimendan is used in the management of severe cardiac conditions that require inotropic support.

- Acute decompensated heart failure: improves cardiac output and reduces symptoms of congestion. - Cardiogenic shock: provides rapid hemodynamic stabilization when conventional therapy is insufficient. - Post‑cardiac surgery low‑output syndrome: supports myocardial contractility during the early postoperative period.

Levosimendan may be associated with several adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Headache: mild to moderate intensity. - Nausea: occasional gastrointestinal discomfort. - Hypotension: transient drop in blood pressure. - Arrhythmias: occasional ventricular or supraventricular ectopic beats.

Serious or Rare Side Effects: - Severe hypotension: marked blood pressure reduction requiring intervention. - Ventricular tachycardia: potentially life‑threatening rhythm disturbance. - Allergic reactions: anaphylaxis or severe skin rash. - Myocardial ischemia: worsening of cardiac ischemia in susceptible patients.

When using Levosimendan, clinicians should observe several precautionary measures to minimise risk.

- Cardiac monitoring: continuous ECG and hemodynamic assessment during infusion. - Blood pressure: monitor for hypotension, especially in patients on vasodilators. - Electrolytes: correct potassium and magnesium abnormalities before administration. - Renal function: adjust use in severe renal impairment as drug clearance may be reduced. - Hepatic function: use caution in patients with significant liver disease. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levosimendan can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Nitrates: combined vasodilation may cause profound hypotension. - Phosphodiesterase‑5 inhibitors: increased risk of severe hypotension. - Beta‑blockers: may blunt desired inotropic response.

Moderate Interactions (Monitor Closely): - Calcium channel blockers: additive cardiovascular effects require monitoring. - Diuretics: may exacerbate electrolyte disturbances and hypotension. - Anticoagulants: monitor for bleeding if hypotension leads to organ hypoperfusion.